Oncolytics Biotech Inc.

oncolytic virus immunotherapy (pelareorep)

ONCY · Nasdaq · United States

Share price · ONCY

$0.44-0.40 (-47.88%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.2M (1.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ONCY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+15.1%
  2. 17 Nov 2026+12.5%
  3. 9 Nov 2026-7.2%
  4. 14 Oct 2026+9.8%
  5. 12 Oct 2026-15.0%
  6. 8 Oct 2026-8.6%
  7. 5 Oct 2026-5.4%
  8. 22 Sep 2026-6.9%

    Nothing announced by ONCY that day or the session before.

  9. 14 Sep 2026+9.0%
  10. 9 Jul 2026+16.1%

Share of unusual movement by asset

For each asset, the share of ONCY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Pelareorep
events and moves
135%
Other company news (earnings, financing, releases naming no asset)—42%
Sessions with no dated event—53%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Tumor cells (oncolytic replication)Oncolytic virus
Colorectal Cancer
Advanced Metastatic Colorectal Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
PelareorepPhase 1/2Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic …
Est. primary completion 2027-07-30 · NCT07280377 · CT.gov ↗
What to watch
August 2027 (1)
PelareorepPhase 2Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
Est. primary completion 2027-08-30 · NCT07446322 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$5.2M$2.4M$9.7M-$6.9M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$4.3M$4.1M$9.4M-$8.1M operating cash flowreport ↗
2026-Q1—$4.5M$5.5M$9.2M-$7.3M operating cash flowreport ↗
2025-Q3—$5.1M$8.9M$9.9M-$4.8M operating cash flowreport ↗
2025-Q2—$1.9M$11M$5.3M-$4.1M operating cash flowreport ↗
2025-Q1—$2.8M$11M$4.7M-$4.7M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$3.8M—-$20M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$16M$7.7M$5.8M-$20M operating cash flowreport ↗
2023-FY—$13M$20M$5.1Mreport ↗
2022-FY—$12M—$4.8Mreport ↗
2021-FY$0$10M—$5.3Mreport ↗

Insider transactions

Open-market activity, trailing 12 months: 14 purchases ($363K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-01Glover Stephen C. · directorAward / grant (derivative)96,000——Form 4
2026-06-01McAdory John Bearden · Chief Operating OfficerAward / grant (derivative)145,000——Form 4
2026-06-01Heineman Thomas Charles · Chief Medical OfficerAward / grant (derivative)260,000——Form 4
2026-06-01Brown Deborah Margaret · directorAward / grant (derivative)30,000——Form 4
2026-06-01Hagerman Allison · Chief Technology OfficerAward / grant (derivative)260,000——Form 4
2026-06-01Seizinger Bernd R. · directorAward / grant (derivative)30,000——Form 4
2026-06-01Andrews Patricia S · directorAward / grant (derivative)30,000——Form 4
2026-06-01Kelly Jared · director, Chief Executive OfficerAward / grant (derivative)755,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2 reporting institutions held 0.9M shares ($731K, 0.7% of shares outstanding).

#InstitutionSharesValue
1MARSHALL WACE, LLP859,831$731K
2Sound Income Strategies, LLC194$180